Radiculopathic Pain Phase II Clinical Trial

In a concerted effort to address the widespread issue of chronic pain, ANANDA Scientific is collaborating with the NYU Grossman School of Medicine, and Stephen Ross, MD to conduct a groundbreaking clinical trial targeting Radiculopathic Pain, often referred to as Chronic Non-Cancer Pain (CNCP) , a pervasive public health challenge and demands a comprehensive and integrated approach for effective management.

Drawing on preclinical evidence, CBD emerges as a promising treatment for radicular CNCP syndromes. Animal studies demonstrate CBD’s potential in reducing pain behaviors and inflammation, particularly in chronic inflammatory and neuropathic pain models. Intriguingly, the combination of opioids and cannabinoids presents synergistic effects, as observed in both animal models and human studies.

Under the guidance of Dr. Stephen Ross, this trial is evaluating Nantheia™ A1002N5S, Ananda’s investigational CBD drug utilizing its proprietary Liquid Structure ™ delivery technology to assess the pivotal outcomes of this integrated approach.

The primary endpoint focuses on the change in opioid maintenance dose from baseline, providing a crucial measure of the intervention’s impact. Additionally, secondary endpoints include evaluations of pain levels, anxiety, sleep quality, and depressive symptoms, affording a comprehensive understanding of the treatment’s holistic effects on participants’ well-being. This collaboration underscores our collective commitment to advancing pain management strategies and enhancing the quality of life for individuals battling chronic pain.

For more details, refer to the clinicaltrials.gov link (https://clinicaltrials.gov/study/NCT04760613) and press releases issued over the course of the study:

1. ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient Enrolled in the Clinical Trial for Opioid Sparing in Participants with Radiculopathic Pain https://www.businesswire.com/news/home/20220308005059/en

2. ANANDA Scientific and NYU Grossman School of Medicine Announce Second Clinical Trial Utilizing Liquid StructureTM Cannabidiol (CBD) for Evaluating Its Effect on Opioid Sparing in Participants with Chronic Radiculopathic Pain Syndromes https://www.businesswire.com/news/home/20210128005188/en